Share this article

Italian medical robotic solutions developer Medical Microinstruments (MMI) has unveiled its new robotic platform for open microsurgery.

Surgeons can use the new platform to control two small articulated microinstruments designed to allow easy reconstruction after traumatic injuries and following tumour removal in soft tissue and bones.

The simplified procedures are in turn expected to enhance surgical success rate and patient outcomes.

The new platform features a small articulated wrist with 3mm outer diameter and 150µ-wide tips intended to facilitate robotic microsurgery in real-time.

The wrist also enables easy manipulation of small sutures with size ranging between 9-0 and 12-0.

The surgeons can operate the microinstruments at the surgical bedside, while using the operating microscope for viewing.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
“We are on the right track in developing a robot by and for microsurgeons.”

MMI designed the new robotic platform to capture surgeon’s hand movements and impose a scaled-down motion on the microinstruments.

Medical Microinstruments co-founder and Clinical vice-president Hannah Teichmann said: “We have developed this groundbreaking technology together with microsurgeons from the product’s conception and the positive feedback and response that we’ve received along the way has really been overwhelming and led us to believe that we are on the right track in developing a robot by and for microsurgeons.”

It is expected that the robotic platform will enable surgeons to carry out more complex procedures and supermicrosurgery such as lymph reconstruction.

The firm’s president and co-founder Giuseppe Maria Prisco estimates that the platform could cater to the potential annual market opportunity of $2.5bn.